天然产物研究与开发 ›› 2025, Vol. 37 ›› Issue (8): 1397-1410.doi: 10.16333/j.1001-6880.2025.8.001 cstr: 32307.14.1001-6880.2025.8.001

• 研究论文 •    下一篇

基于肠道菌群测序和代谢组学分析探究黄连-干姜药对治疗溃疡性结肠炎的作用机制

黄成银†,程  雯†,张苗苗,王  征,侯宝龙,梁艳妮*   

  1. 陕西中药资源产业化省部共建协同创新中心;秦药特色资源研究与开发国家重点实验室(培育);陕西中医药大学,咸阳 712083
  • 出版日期:2025-08-25 发布日期:2025-08-25
  • 基金资助:
    国家自然科学基金(82474386);陕西省教育厅创新团队项目(24JP047);秦创原中医药产业创新聚集区项目(L2024-QCY-ZYYJJQ-X195)

Therapeutic mechanism of Coptidis Rhizoma-Zingiberis Rhizoma drug pair in ulcerative colitis based on gut microbiota sequencing and metabolomics analysis

HUANG Cheng-yin†, CHENG Wen†, ZHANG Miao-miao, WANG Zheng, HOU Bao-long, LIANG Yan-ni*   

  1. Co-construction Collaborative Innovation Center of Chinese Medicine Resources Industrialization by Shaanxi & Education Ministry;State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation);Shaanxi University of Chinese Medicine,Xianyang 712083,China
  • Online:2025-08-25 Published:2025-08-25

摘要:

为探究黄连-干姜(Coptidis Rhizoma-Zingiberis Rhizoma,CR-ZR)配伍对葡聚糖硫酸钠(dextrose sodium sulfate,DSS)诱导的溃疡性结肠炎(ulcerative colitis,UC)小鼠肠道菌群及内源性代谢物的影响。采用HPLC技术检测CR-ZR主要活性成分;将雄性C57BL/6小鼠随机分成6组:空白组、模型组、柳氮磺胺吡啶组(125 mg/kg)、CR-ZR低剂量组(22.5 mg/kg)、CR-ZR中剂量组(45 mg/kg)、CR-ZR高剂量组(90 mg/kg),每组10只,除对照组外,其余组均饮用2.5% DSS建立UC模型,造模过程中同时灌胃给药总计11 d,每日记录小鼠体重变化、粪便性状和隐血情况进行疾病活动指数(disease activity index,DAI)评分。采用HE进行结肠组织染色,运用ELISA法评估肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-4(interleukin-4,IL-4)、IL-6、IL-8和IL-10等细胞因子水平,结合16S rRNA测序分析肠道菌群变化,并采用UPLC-MS技术进行广泛靶向代谢组学分析。结果显示,与模型组对比,CR-ZR药对可显著降低UC小鼠DAI评分(P<0.01),减轻结肠组织损伤,减少炎性细胞浸润,下调血清中促炎细胞因子IL-6、IL-8和TNF-α水平(P<0.01),促进抑炎细胞因子IL-10和IL-4分泌(P<0.01)。16S rRNA基因测序结果显示,CR-ZR处理后小鼠肠道菌群拟杆菌门/厚壁菌门(Bacteroidota/Firmicutes)比例、拟普雷沃氏菌属(Alloprevotella)、LachnoclostridiumMucispirillum、经黏液真杆菌属(Blautia)丰度均呈现向健康态恢复的趋势。代谢组学分析筛选出20个生物标志物与CR-ZR药对调节效应相关,涉及精氨酸生物合成、色氨酸代谢途径。说明CR-ZR药对通过重塑紊乱的肠道微生态并调控精氨酸生物合成和色氨酸代谢改善UC。

关键词: 黄连, 干姜, 溃疡性结肠炎, 肠道菌群, 代谢组学

Abstract:

This study aims to investigate the effect of Coptidis Rhizoma-Zingiberis Rhizoma (CR-ZR) on gut microbiota and endogenous metabolites in mice with ulcerative colitis (UC) induced by dextran sodium sulfate (DSS). The principal active constituents of CR-ZR were determined via high-performance liquid chromatography (HPLC) analysis. Male C57BL/6 mice were randomly assigned to six groups: control, model, sulfasalazine (125 mg/kg), low-dose CR-ZR (22.5 mg/kg), medium-dose CR-ZR (45 mg/kg), and high-dose CR-ZR (90 mg/kg), with 10 mice in each group. To establish the UC model, all groups except the control were given 2.5% DSS in drinking water and subjected to gavage treatment for 11 days. Daily records of changes in body weight, fecal characteristics, and occult blood were maintained to determine the disease activity index (DAI). HE staining was used for colonic histological evaluation. The levels of cytokines including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-8, IL-4 and IL-10 were measured using ELISA. Furthermore, the gut microbiota was analyzed through 16S rRNA sequencing, and widely targeted metabolomic analysis was performed using UPLC-MS. Compared with the model group, the results indicated that CR-ZR treatment significantly reduced DAI scores (P<0.01), colonic histological damage, and inflammatory cell infiltration in colitis mice. Serum levels of pro-inflammatory cytokines (TNF-α, IL-6 and IL-8) significantly decreased, whereas anti-inflammatory cytokine levels (IL-4 and IL-10) were markedly elevated (P<0.01). 16S rRNA gene sequencing indicated that the Bacteroidota/Firmicutes ratio and the relative abundances of Alloprevotella, Lachnoclostridium, Mucispirillum, and Blautia in mice treated with CR-ZR suggested a trend towards a healthier state. Metabolomic analysis identified 20 biomarkers associated with the regulatory effects of CR-ZR, primarily involved in arginine biosynthesis and tryptophan metabolism pathways. These findings indicate that CR-ZR ameliorates UC by remodeling the disordered gut microbiota and regulating arginine biosynthesis and tryptophan metabolism.

Key words: Coptidis Rhizoma; Zingiberis Rhizoma, ulcerative colitis, gut microbiota, metabolomics

中图分类号:  R285.5